Results 41 to 50 of about 325,639 (307)
Lung IndiaIntroduction and Objective: Heterogeneity in locally advanced (LA) Non-Small Cell Lung Cancer (NSCLC) group necessitates a multi-disciplinary approach to its management. Surgery is the standard of care treatment if resectable; otherwise, concurrent chemo-
Aswin Ravi +5 more
doaj +1 more source
Cancer Management and Research, 2023 Dai J, Wang B, Zhao Y, et al. Cancer Manag Res. 2020;12:12697–12708. At the authors request, the Editor and Publisher of Cancer Management and Research wish to retract the published article.
Dai J +6 more
doaj
Role of Serum Tumor Markers in Prognosis of Operable Non-small Cell Lung Cancer Patients
Zhongliu Fangzhi Yanjiu, 2018 Objective To evaluate the prognostic value of CEA, CA125, CA199, NSE, CYFRA21-1 and SCC-Ag as serum tumor markers on the diagnosis of operable non-small cell lung cancer(NSCLC) after radical operation.
LI Shaolei +5 more
doaj +1 more source
Pharmaceutics, 2020 c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially ...
Nam Ah Kim +8 more
doaj +1 more source
Angiogenesis Inhibitors in NSCLC [PDF]
International Journal of Molecular Sciences, 2017 Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy ...
Manzo, Anna +10 more
openaire +2 more sources
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. [PDF]
, 2018 Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune system is via overexpression of programmed ...
Che, James +10 more
core +3 more sources
IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages
International Journal of General Medicine, 2023 Xiao Chen,1,2 Jie Yao,1 Meng-Yu Zhang,1 Rui Li,1 Xiao Liu,1 Yi-Qing Qu1 1Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 2Department of Respiratory Medicine, Tai’an City Central
Chen X +5 more
doaj
Lung Cancer: Targets and Therapy, 2021 State-of-the-art cancer precision medicine approaches involve targeted inactivation of chemically and immunologically addressable vulnerabilities that often yield impressive initial anti-tumor responses in patients. Nonetheless, these responses are overshadowed by therapy resistance that follows. AXL, a receptor tyrosine kinase with bona fide oncogenic
Zaman,Aubhishek, Bivona,Trever G
openaire +4 more sources
Open Life SciencesCell proliferation and epithelial–mesenchymal transition (EMT) are two common tumor phenotypes closely linked to malignant tumor progression. Genes regulating tumor progression often exhibit consistent regulatory trends in these phenotypes; however ...
Tan Xinyu +4 more
doaj +1 more source
Hydroxygenkwanin Suppresses Non-Small Cell Lung Cancer Progression by Enhancing EGFR Degradation
Molecules, 2020 Epidermal growth factor receptor (EGFR) is frequently overexpressed and mutated in non-small cell lung cancer (NSCLC), which is the major type of lung cancer.
Yann-Lii Leu +6 more
doaj +1 more source